  Prognosis on the occurrence of relapses in individuals with
Relapsing-Remitting Multiple Sclerosis (RRMS), the most common subtype of
Multiple Sclerosis (MS), could support individualized decisions and disease
management and could be helpful for efficiently selecting patients in future
randomized clinical trials. There are only three previously published
prognostic models on this, all of them with important methodological
shortcomings.
  We aim to present the development, internal validation, and evaluation of the
potential clinical benefit of a prognostic model for relapses for individuals
with RRMS using real world data. We followed seven steps to develop and
validate the prognostic model. Finally, we evaluated the potential clinical
benefit of the developed prognostic model using decision curve analysis.
  We selected eight baseline prognostic factors: age, sex, prior MS treatment,
months since last relapse, disease duration, number of prior relapses, expanded
disability status scale (EDSS), and gadolinium enhanced lesions. We also
developed a web application where the personalized probabilities to relapse
within two years are calculated automatically. The optimism-corrected
c-statistic is 0.65 and the optimism-corrected calibration slope was 0.92. The
model appears to be clinically useful between the range 15% and 30% of the
threshold probability to relapse.
  The prognostic model we developed offers several advantages in comparison to
previously published prognostic models on RRMS. Importantly, we assessed the
potential clinical benefit to better quantify the clinical impact of the model.
Our web application, once externally validated in the future, could be used by
patients and doctors to calculate the individualized probability to relapse
within two years and to inform the management of their disease.
